Systemic Diseases and Syndromes that Affect the Periodontium

This chart includes medical conditions known to impact periodontal health and that may be included in a differential diagnosis when periodontitis is detected in pediatric patients. Individualized at-home and professional preventive oral care interventions must be emphasized for these patients. A multidisciplinary approach may be indicated for safe and effective oral health care.

Disorder	General characteristics	Diagnostic criteria	Oral findings		Treatment
			Clinical	Radiographic	considerations
Chédiak-Higashi syndrome ^{1,2}	Rare autosomal recessive disorder of the immune system Mild 'atypical' phenotype: 10-15% of cases; 'classic' phenotype: 80-90%, progresses to accelerated phase (fatal without bone marrow transplant) Characterized by reduced pigmentation, neurological deficits, fever, lymphadenopathy, anemia, neutropenia, hepatosplenomegaly thrombocytopenia.	Microscopic analysis of WBCs Genetic testing identifies mutations in the lysosomal trafficking regulator gene (LYST/CHS1)	- Severe gingival inflammation, swelling, and recession - Early onset periodontitis in primary and permanent dentitions - Premature tooth loss - Oral ulcerations may be present	Alveolar bone loss (localized or generalized)	Immune status and transplantation dictate timing and precautions (e.g., antibiotics) Supportive management of complications (e.g., antibiotics to treat bacterial infections) Aggressive recurrent periodontitis may not respond to SRP or antibiotic treatment For extractions/surgeries, consider adjunctive measures for hemostasis and avoid NSAIDs due to platelet dysfunction Prosthetic therapy for lost teeth may be considered depending on patient's medical status
Diabetes mellitus ^{3,4}	Metabolic disorder Type 1: autoimmune reaction causes lack of insulin production; usually diagnosed in children and young adults Type 2: insulin resistance; usually diagnosed in adults Gestational: insulin resistance during pregnancy Associated with increased inflammation, impaired immunologic response and wound healing, CV disease, retinopathy, nephropathy, neuropathy	- Glycated hemoglobin (A1C) - Other tests include: oral glucose tolerance tests, fasting plasma glucose test, random plasma glucose test	- Enlarged, erythematous attached gingiva - Dental/ periodontal abscesses - Increased clinical attachment loss and pathologic periodontal pockets - Severe periodontitis	Alveolar bone loss	Assess level of disease control (e.g., compliance with diet and medications) With uncontrolled diabetes, consider antibiotic prophylaxis for invasive oral procedures Nonsurgical periodontal therapy (e.g., SRP and antimicrobial agents [chlorhexidine, antibiotics]) shows modest glycemic control improvement Monitor for delayed healing
Haim-Munk syndrome ^{4,5}	Rare autosomal recessive syndrome; a phenotypic variant of PLS with mutation to chromosome 11q14-q21 and loss of function of the cathepsin C gene Milder periodontal disease and more severe dermatologic manifestations than PLS Clinical manifestations Dermatologic: palmoplantar hyperkeratosis; scaly patches on eyelids, lips, cheeks; skin infections Skeletal: arachnodactyly, onychogryphosis, acroosteolysis, pes planus, muscle contractures, and destructive arthritis	Genetic testing for mutation of cathepsin C gene	- Rapidly advancing gingival inflammation and bleeding, deep periodontal pockets, gingival abscesses, periodontal destruction - Premature loss of all primary teeth by age 4-5; loss of permanent teeth by age 16 - After tooth loss, gingiva returns to healthy state	Generalized extensive alveolar bone loss with migration of teeth	Treatment of oral manifestations depends on patient's age, psychological state, and tooth mobility May include nonsurgical therapy (e.g., monthly SRP, systemic antibiotics) and/or extraction of hopeless teeth Alveolar loss renders prosthetic rehabilitation challenging Table continued on the next page.

Abbreviations in table: BMI: Body mass index; CDC: Centers for Disease Control and Prevention; CV: cardiovascular; NSAIDs: nonsteroidal anti-inflammatory drugs; PLS: Papillon Lefèvre syndrome; SRP: Scaling and root planing; WBCs: White blood cells.

Disorder	General characteristics	Diagnostic criteria	Oral findi	Treatment	
			Clinical	Radiographic	considerations
Hypophos- phatasia ^{6,7}	Rare genetic metabolic bone disorder characterized by impaired mineralization of bones and/or teeth Mutations in the ALPL gene leading to low alkaline phosphatase activity Wide-ranging severity (involving skeletal, renal, neurological, muscular, respiratory complications); six types based on severity and age of onset Disturbed cementum formation; tooth loss is one of the first signs of the condition	Serum alkaline phosphatase (ALP) levels ALPL gene testing	Premature exfoliation of primary teeth with little or no root resorption Clinical inflammation milder than in other systemic diseases associated with periodontitis Permanent dentition may be clinically normal in mild subtypes or prone to periodontitis and early tooth loss in severe cases	Alveolar bone loss Large pulpal chambers and root canals Thin dentin	- Enzyme replacement therapy, a new disease-modifying treatment, has shown periodontal, tooth, and bone improvements - Caution with orthodontic management due to cementum dysplasia and impaired periodontal attachment - Prosthodontic therapy may include removable prostheses and possible implants to stabilize prosthesis in the permanent dentition for those skeletally mature
Langerhans cell histio- cytosis ⁸	Rare cancer-like condition (inflammatory myeloid neo- plasia) characterized by excessive proliferation/ infiltration of histiocytes (Langerhans cells); form categorized as a single- system (single organ affected) or multisystem (several organs affected) Mortality rate: < 10% in single-system vs. 30-50% in multisystem Average age of onset: 1-3 years; male predilection Oral manifestations and pain can be the first signs of the condition	Clinical, microscopic, hematologic, and imaging examinations	Gingivitis, bleeding, recession, mucosal swelling, periodontitis, ulceration Excessive mobility of teeth, premature exfoliation Oral pain	Alveolar bone loss with distinct appearance of teeth floating in soft tissue Unifocal or multiple lesions within the body of the maxilla and mandible	- Management of periodontal disease is not the first-line of treatment - Treatment of oral lesions depends on the type/ extent of disease and may vary from observation to pharmacotherapy, surgical excision/curettage, and/or radiation therapy - Treatment should include basic periodontal therapy and extractions of hopeless teeth depending on immune status
Leukocyte adhesion deficiency syndromes ^{4,9}	Rare autosomal recessive disorders Primary immunodeficiency disorder involving both B and T cells Impaired migration of WBCs to infection sites Recurrent nonpyogenic bacterial and fungal mucosal infections Compromised wound healing Hematopoietic stem cell transplantation is the only curative treatment; high mortality rate	- Elevated WBCs (leukocytosis) - Genetic testing to identify mutations - Flow cytometry analysis to evaluate neutrophil expressions - Key clinical finding: absence of pus at site of infection	Aggressive and severe gingivitis and rapidly progressive periodontitis Persistent oral ulcers (gingivostomatitis) Absence of pus Premature exfoliation of primary dentition and early loss of permanent teeth	Alveolar bone loss	Periodontal disease may be refractory to nonsurgical periodontal treatment and rigorous home care regimens Prompt targeted antibiotic therapy Adjunctive treatment may include granulocyte/ thrombocyte transfusions, recombinant factor VIIa, and intravenous immunoglobulins Prophylactic antibiotics prior to dental procedures
Obesity ¹⁰	Chronic complex multifactorial metabolic disorder presenting as excessive accumulation of fat Etiologies: genetic, neuro-endocrine, drug-induced, behavioral (diet and activity) Comorbidities: diabetes, hypertension, CV disease, obstructive sleep apnea, systemic inflammation, some cancers	Measured BMI Ages 2-19: ≥ 95th percentile or ≥ 30 kg/m², whichever is lower based on age and gender using CDC growth charts Adult: ≥ 30 kg/m² Other measures include: waist/hip circumferences, waist to hip ratios	Increased plaque index, bleeding on probing, periodontal pocket depth, clinical attachment loss Mouth breathing	Alveolar bone loss	Comorbidities may influence management Dietary weight loss may reduce systemic inflammation and, in turn, enhance response to periodontal therapy

Abbreviations in table: BMI: Body mass index; CDC: Centers for Disease Control and Prevention; CV: cardiovascular; NSAIDs: nonsteroidal anti-inflammatory drugs; PLS: Papillon Lefèvre syndrome; SRP: Scaling and root planing; WBCs: White blood cells.

Disorder	General characteristics	Diagnostic criteria	Oral findings		Treatment
			Clinical	Radiographic	considerations
Papillon Lefèvre syndrome (PLS) ¹¹	 Autosomal recessive disorder Palmoplantar hyperkeratosis, nail dystrophy, pyogenic skin and other infections, intracranial calcification Rapidly progressing periodontal manifestations beginning shortly after tooth eruption; occurs in primary and permanent dentitions Etiology: alterations in the CTSC gene and, likely, neutrophil defects 	Urinalysis for cathepsin C activity Genetic testing for mutation of cathepsin C gene Key clinical finding: periodontal degeneration	- Rapidly advancing gingival inflammation and bleeding, deep periodontal pockets, gingival abscesses, periodontal destruction - Premature loss of all primary teeth by ages 4-5; loss of permanent teeth by age 16 - After tooth loss, gingiva returns to healthy state	Generalized extensive alveolar bone loss with migration of teeth	Treatment of oral manifestations depends on patient's age, psychological state, and tooth mobility May include nonsurgical therapy (e.g., monthly SRP, systemic antibiotics) and/or extraction of hopeless teeth Alveolar loss renders prosthetic rehabilitation challenging
Periodontal Ehlers- Danlos syndrome ^{12,13} (Synonyms: Ehlers-Danlos syndrome VIII; pEDS)	- One of a group of hereditable connective tissue disorders; autosomal dominant - Characterized by varying features including tissue fragility with easy bruising, vascular complications, joint hypermobility and/or pain, pretibial discoloration/plaques, increased infection rate, hoarse voice - Predominant feature is severe early-onset periodontitis (mean age 14)	- Clinical examination and molecular genetic testing (variant in the genes C1R and C1S which play a role in innate immune system) - Complete lack of gingival attachment is considered pathognomonic - Most children identified through family history	Severe gingival inflammation, loss of attached gingiva, and gingival thinning and recession Rapid alveolar bone loss Premature tooth loss	Alveolar bone loss	May include nonsurgical therapy (e.g.,monthly SRP, systemic antibiotics) and/or extraction of hopeless teeth Alveolar loss renders prosthetic rehabilitation challenging Implants at high risk of peri-implantitis

Abbreviations in table: BMI: Body mass index; CDC: Centers for Disease Control and Prevention; CV: cardiovascular; NSAIDs: nonsteroidal anti-inflammatory drugs; PLS: Papillon Lefèvre syndrome; SRP: Scaling and root planing; WBCs: White blood cells.

References

- 1. Thumbigere Math V, Rebouças P, Giovani PA, et al. Periodontitis in Chédiak-Higashi syndrome: An altered immunoinflammatory response. JDR Clin Trans Res 2018;3(1):35-46. Available at: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC573 4460/'. Accessed September 21, 2022.
- 2. National Organization for Rare Disorders (NORD). Chédiak Higashi Syndrome. Available at: "https://rarediseases.org/rare -diseases/chediak-higashi-syndrome/". Accessed September 1, 2022.
- 3. American Diabetes Association. Diabetes Overview. Understanding A1c. Diagnosis. Available at: "https://diabetes.org/diabetes/a1c/diagnosis". Accessed September 21, 2022.
- 4. Albandar JM, Susin C, Hughes FJ. Manifestations of systemic diseases and conditions that affect the periodontal attachment apparatus: Case definitions and diagnostic considerations. J Periodontol 2018;89(Suppl 1):S183-S203.
- 5. National Organization for Rare Disorders (NORD). Haim-Munk Syndrome. Available at: "https://rarediseases.org/rare-diseases/haim-munk-syndrome/". Accessed September 1, 2022.
- 6. National Organization for Rare Disorders (NORD). Hypophosphatasia. Available at: "https://rarediseases.org/rare-diseases/hypophosphatasia/". Accessed September 1, 2022.
- 7. Okawa R, Kokomoto K, Nakano K. Dental effects of enzyme replacement therapy in case of childhood-type hypophosphatasia. BMC Oral Health 2021;21(1):323.
- 8. National Organization for Rare Disorders (NORD). Langerhans Cell Histiocytosis. Available at: "https://rarediseases.org/rare-diseases/papillon-lefevre-syndrome/". Accessed September 1, 2022.
- 9. National Organization for Rare Disorders (NORD). Leukocyte Adhesion Deficiency Syndromes. Available at: "https://rare diseases.org/rare-diseases/leukocyte-adhesion-deficiency-syndromes/". Accessed September 1, 2022.
- 10. National Collaborative on Childhood Obesity Research. A Guide to Methods for Assessing Childhood Obesity: Overview of Body Composition and Measuring Adiposity. Available at: "https://www.nccor.org/tools-assessingobesity-guide/overview-of-body-composition-and-measuring-adiposity/#two-c". Accessed August 24, 2022.
- 11. National Organization for Rare Disorders (NORD). Papillon Lefèvre Syndrome. Available at: "https://rarediseases.org/rare-diseases/papillon-lefevre-syndrome/". Accessed August 24, 2022.
- 12. Kapferer-Seebacher I, van Dijk FS, Zschocke J. Periodontal Ehlers-Danlos Syndrome. In: Adam MP, Everman DB, Mirzaa GM, et al., eds. GeneReviews® [Internet]. Seattle, Wash.: University of Washington, Seattle; 2021:1993-2022. Available at: "https://www.ncbi.nlm.nih.gov/books/NBK572429/#." Accessed August 24, 2022.
- 13. Rinner A, Zschocke J, Schossig A, Gröbner R, Strobl H, Kapferer-Seebacher I. High risk of peri-implant disease in periodontal Ehlers-Danlos Syndrome. A case series. Clin Oral Implants Res 2018;29:1101-6.